Gene-virus Interactions Implicated in Type 1 Diabetes
NCT02804165 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL
Last updated 2018-05-11
Summary
Type 1 diabetes (T1D) is the most common endocrine disorder in children. In France, T1D prevalence is estimated to 12.2 per 100 000. Worldwide T1D incidence increased rapidly in the last decades, around 3% per year. T1D is caused by autoimmune destruction of pancreatic beta cells, leading to hyperglycaemia. T1D was recently associated an important loss in life expectancy compared with the general population. To date, the precise aetiology of T1D onset and the mechanisms involved in T1D remain unknown and no preventive treatment of T1D exists.
It is now well admitted that T1D results from a combined effect of genes, environmental factors and gene-environment interactions. Several genetic factors have been reported as associated to T1D, the most important being the human leukocyte antigen class II genes. Whole genome association studies suggested more than 50 T1D other susceptibility locus, but conferring individually a modest risk to develop T1D. Longitudinal studies demonstrated that only a low fraction of genetically predisposed subjects develop T1D and all these genetic factors cannot explain the increase in prevalence of T1D in the latter half of the 20th century, suggesting the implication of environmental factors.
Literature has accumulated a lot of evidence for the role of enterovirus in T1D. Several retrospective, prospective, post-mortem human studies, as well as animal studies, strongly suggest contribution of human enteroviruses to the pathogenesis of T1D. Enterovirus probably play a dual role in T1D, some enterovirus being associated with an increased risk of T1D and others with a protective effect. Interestingly, several T1D susceptibility loci are implicated in antiviral response. Epidemiologic and genetic approaches have led to new insights into T1D causation, but a collective explanation is still lacking.
The project aims at (1) demonstrating the gene-enterovirus interaction effect on T1D onset and (2) characterizing the "precipitating" effect of enterovirus on T1D by a follow-up study of T1D high-risk subjects (first degree unaffected relatives with positive autoantibodies to islet antigens).
A structural originality of this project is to perform a family-based study of gene-enterovirus interaction in T1D using innovative and robust methods. This project will be conducted in close collaboration between our INSERM unit, the Inter-regional network of paediatric diabetology, labelled biobanks (CBC Biotec of Hospices Civils de Lyon and CRB-LRB of Lariboisière' hospital at Paris), the Centre National de Référence des Enterovirus at Lyon and the Centre National de Génotypage at Evry.
The investigators will first conduct a 3-years pilot study (2016-2019), based on a sample of 250 nuclear families ascertained through a paediatric T1D proband in four centres. Families will be ascertained during the hospitalization of the proband at the time of T1D diagnosis. The study will be then extended to whole Inter-regional network of paediatric diabetology.
This research is a unique opportunity to explore further the implication of enterovirus and their interactions with genetic factors involved in T1D susceptibility and aims to target high-risk T1D subjects. This innovative project opens the door of the development of preventive therapy for T1D.
Conditions
Interventions
- GENETIC
-
Enterovirus vaccination
Enterovirus vaccination in genetically predisposed subjects having a high risk to develop type 1 diabetes.
Sponsors & Collaborators
-
Hospices Civils de Lyon
lead OTHER
Principal Investigators
-
Marc Nicolino, MD · HCL
Study Design
- Allocation
- NA
- Purpose
- BASIC_SCIENCE
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 1 Year
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-01-31
- Primary Completion
- 2022-07-31
- Completion
- 2022-07-31
Countries
- France
Study Locations
More Related Trials
-
A Study of LY3532226 in Participants With Type 1 Diabetes Mellitus
NCT05887999 ·Status: COMPLETED ·Phase: PHASE1
-
Circulating Biomarkers in the Development of Type 1 Diabetes
NCT05505669 ·Status: RECRUITING
-
Effect of Weekly GLP1 Agonist Treatment in "Double Diabetes"
NCT05305794 ·Status: RECRUITING ·Phase: PHASE3
-
Dulaglutide and Insulin MicrosecretiON in Type 1 Diabetes
NCT03668470 ·Status: COMPLETED ·Phase: PHASE2
-
Pancreatic Enzyme Replacement and Glucose Regulation in Type 1 Diabetes
NCT05266963 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Effect of GLP-1 on Insulin-dose, Risk of Hypoglycemia and Gastric Emptying Rate in Patients With Type 1 Diabetes
NCT00993720 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study of Insulin Peglispro and Glargine on Fats in Participants With Type 1 Diabetes
NCT01771250 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Adiposity on Hepatic and Peripheral Insulin Resistance in Type 1 Diabetes
NCT03582956 ·Status: TERMINATED ·Phase: NA
-
GLP-1/Basal Insulin Combination Therapy
NCT02895672 ·Status: COMPLETED
-
Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS)
NCT02914886 ·Status: COMPLETED ·Phase: PHASE4
-
Physiologic Markers of Cardiometabolic Risk in People With Type 1 Diabetes
NCT06105931 ·Status: RECRUITING ·Phase: PHASE1
-
Glucagon-like Peptide-1 in Type 1 Diabetes
NCT04355832 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
Liraglutide in Adolescents With Type 1 Diabetes
NCT02516657 ·Status: COMPLETED ·Phase: PHASE3
-
Polyclonal Anti-T-Lymphocyte Globulin (ATG) in Type 1 Diabetes
NCT00190502 ·Status: UNKNOWN ·Phase: NA
-
Optimising Health in Type 1 Diabetes
NCT02903615 ·Status: COMPLETED ·Phase: NA
-
Develop and Validate a Self-Administered Instrument That Will Screen for Eating Disorder Symptoms in Persons Aged 12 and Older With Type 1 Diabetes.
NCT00948311 ·Status: COMPLETED
-
Very Low Carbohydrate Diets and Glucagon Response in T1DM
NCT04200391 ·Status: RECRUITING ·Phase: NA
-
Liraglutide in Type 1 Diabetes
NCT01612468 ·Status: COMPLETED ·Phase: PHASE4
-
Body Mass Index and Growth Parameters Evolution in Children Treated With Hybrid Closed Loop System for Type 1 Diabetes
NCT06185348 ·Status: NOT_YET_RECRUITING
-
The Importance of GLP-1 in Post RYGB Improvement in Glycaemic Control Type 2 Diabetic Subjects
NCT01579981 ·Status: COMPLETED ·Phase: NA
-
Carvedilol in Treating Hypoglycemia Unawareness
NCT03538015 ·Status: TERMINATED ·Phase: PHASE2
-
Glucagon-Like Peptide-1 (GLP-1) Suppression of Alpha Cell Secretion in Type 2 Diabetes Mellitus (T2DM)
NCT00862589 ·Status: COMPLETED ·Phase: NA
-
β-cell Function in Type 1 Diabetes May Not Be As Low As Presumed
NCT02199470 ·Status: COMPLETED
-
Endothelial and Metabolic Effects of Glucagon-like Peptide-1 (GLP-1) in Coronary Circulation in Patients With Type 2 Diabetes Mellitus
NCT00923962 ·Status: COMPLETED ·Phase: NA
-
Cardiovascular Effects of Rapidly Declining Plasma Glucose in Patients With Type 1 Diabetes
NCT04800536 ·Status: COMPLETED ·Phase: NA